A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin

Table 2 Comparison of glucose variability in the two groups between baseline and endpoint

Variables	Dapagliflozin (n = 14)			DPP-4 inhibitors (n = 15)			Change difference between groups p value
Variables	Baseline	Endpoint	Mean change (95% CI)	Baseline	Endpoint	Mean change (95% CI)	Change difference between groups p value
MAGE (mg dL⁻¹)	86.0 ± 29.4	91.0 ± 34.2	5.0 (−11.6 to 21.7)	89.8 ± 24.1	105.0 ± 30.9	15.2 (−3.8 to 34.3)	0.39
24-h mean blood glucose (mg dL⁻¹)	147.4 ± 26.6	144.6 ± 22.7	−2.8 (−13.6 to 8.0)	150.5 ± 21.8	155.2 ± 26.1	4.7 (−7.1 to 16.4)	0.32
24-h SD values glucose levels	35.3 ± 11.4	39.1 ± 11.7	3.9 (−1.7 to 9.4)	37.5 ± 8.5	43.6 ± 11.7	6.1 (0.0 to 12.3)	0.56
24-h AUC > 180 (mg dL⁻¹ day⁻¹)	6.9 ± 6.3	6.9 ± 6.1	−0.1 (−4.0 to 3.9)	7.3 ± 6.3	11.6 ± 10.0	4.2 (0.6 to 7.8)	0.09
24-h AUC < 70 (mg dL⁻¹ day⁻¹)	0 (0–0)	0.1 (0–0.3)	0 (−0.5 to 1.0)	0 (0–0.1)	0 (0–0.1)	0.0 (−1.0 to 0.5)	0.21^†
Nighttime AUC < 70 (mg dL⁻¹ day⁻¹)	0 (0–0)	0 (0–0.4)	0 (0 to 1.0)	0 (0–0)	0 (0–0)	0.0 (−0.2 to 1.0)	0.05^†
The total insulin dose (U kg⁻¹)	0.23 ± 0.19	0.23 ± 0.21	0.00 (−0.03 to 0.02)	0.25 ± 0.13	0.25 ± 0.13	0.00 (−0.01 to 0.01)	0.64

Baseline data are presented as the mean ± SD or median (25–75% CI). p values: mean changes from baseline to the end of the study between the Dapagliflozin group and the DPP-4 inhibitors group. ^† Mann–Whitney U test
MAGE mean amplitude of glycemic excursions, 24-h all day, SD standard deviation, AUC area under the curve, nighttime 00:00 to 08:00 h

ISSN: 1758-5996